Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More
Clinical Trials and Novel Therapies
Search our featured clinical trials & novel therapies
Featured Brain Tumor Trials
9-ING-41 in Pediatric Patients With Refractory Malignancies
Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016)
GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
Featured Bone Tumor Trials
Featured Ewing Sarcoma Trials
Featured Hematology Trials
Featured Histiocytosis Trials
Featured Immune Hematology Trials
Featured Immunotherapy Trials and Novel Therapies
Administration of rapidly generated LMP, BARF1 and EBNA1 specific cytotoxic T-lymphocytes to patients with EBV-positive lymphoma
GINAKIT2 - Treatment for neuroblastoma (H-41033)
New immunotherapy for children with hepatoblastoma or hepatocellular carcinoma
Vaccination to enhance the antitumor activity of GD2 chimeric antigen receptor expression VZV-specific T cells in subjects with advanced sarcomas
Featured Leukemia Trials and Novel Therapies
ADVL1411 — A Phase I/II study of BMN673 plus Temozolomide
T2016-003: Epigenetic Reprogramming in Relapsed/Refractory AML
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)Featured Liver Tumor Trials
New immunotherapy for children with solid tumors including liver, kidney and additional rare cancers
Featured Lymphoma Trials
9-ING-41 in Pediatric Patients With Refractory Malignancies
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Featured Neuroblastoma Trials
Featured Retinoblastoma Trials
Featured Solid Tumor Trials
9-ING-41 in Pediatric Patients With Refractory Malignancies
GINAKIT2 - Treatment for neuroblastoma (H-41033)
New immunotherapy for children with solid tumors including liver, kidney and additional rare cancers
Featured Thyroid Cancer Trials
Featured Vascular Anomalies Trials
- Subjects will be identified from the population of patients diagnosed with PIK3CA-related Overgrowth Spectrum (PROS), receiving medical care from the Cancer and Hematology Center and Vascular Anomalies Center at Texas Children’s Hospital. Up to ten (10) patients will be enrolled overall.
- Participants will be enrolled into two age groups: Group 1: ≥ 18 years old and Group 2: 6-17 years old.
- All Sexes are Eligible
- Subjects will include participants with PROS or PS who are currently receiving miransertib as part of Study MK-7075-002 (also known as the MOSAIC study or ArQule’s compassionate use/expanded access program. At our site participants will enter this study as an extension of the ARQ MOSAIC study.
- All Sexes are Eligible
Anticoagulation Effects on Quality of Life in Patients with Slow-flow Vascular Malformations
- Presence of a slow-flow vascular malformation
- ≥2 years old to 99 years old
- Determined to need and eligible for anticoagulation therapy at the discretion of the treating physician per standard of care
- Informed consent provided, and if applicable, child assent provided
- All Sexes are Eligible
For a complete list of clinical trials offered at Texas Children's Hospital, visit clinicaltrials.gov

As a recognized leader in clinical and laboratory research, Texas Children’s Cancer and Hematology Center offers clinical trials for a wide range of children’s cancer and blood disorders. The trials we offer are the result of physician scientists pioneering the translation of breakthrough research findings from the laboratory to the clinic.
We have over 350 researchers in 47 laboratories performing cutting-edge research and over 250 active therapeutic clinical trials, many of which are only available at Texas Children’s. We work closely with the pharmaceutical industry to make important new agents available for children with cancer and blood disorders.
Our physicians develop trials and participate in all major pediatric cancer and blood disorder cooperative clinical trial groups, like the Children’s Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC).
Over 80% of our patients are involved in a clinical trial or study since research shows that children treated on a clinical trial have better outcomes. Every eligible patient is considered for entry in National Cancer Institute-approved trials, and the vast majority are registered in these studies. We work closely with referring physicians and families to identify appropriate options for each individual child and to support the child and the whole family through the entire treatment process.
Interested in learning more?